Patents by Inventor Jose Nieva

Jose Nieva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9814771
    Abstract: The role of a specific E2 region containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination. Protection was evidenced by absence of clinical signs related with CSF as well as the absence of viremia produced by the challenge virulent virus.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 14, 2017
    Assignees: The United States of America, as represented by The Secretary of Agriculture, The University of Connecticut, Universidad del Pais Vasco/Euskal Herriko Univertsitatea (UPV-EHU)
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva
  • Publication number: 20170128563
    Abstract: The role of a specific E2 region, 869CKWGGNWTCV878, containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. A recombinant CSFV (FPi.c) containing mutations in three amino acid residues within the E2 protein area comprised CSFV amino acid residues 869-878 was constructed: W871T, W875D, and V878T. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination.
    Type: Application
    Filed: September 8, 2016
    Publication date: May 11, 2017
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva